US2010260732A1PendingUtilityA1

Role for sry in parkinson's disease

33
Assignee: PRINCE HENRYS INST MED RESPriority: Feb 21, 2007Filed: May 6, 2010Published: Oct 14, 2010
Est. expiryFeb 21, 2027(~0.6 yrs left)· nominal 20-yr term from priority
Inventors:Vincent Russel HarleyEric Vilain
C12N 2510/00A61K 38/1709C12N 2501/60A61P 25/16A61K 48/0075A61K 35/30C12N 5/0619A61P 25/28
33
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method for treating or preventing Parkinson's disease in a patient, the method comprising administering to the patient a therapeutically effective population of neuronal cells transformed with a nucleic acid molecule encoding SRY, wherein the transformed cells express SRY.

Claims

exact text as granted — not AI-modified
1 .- 11 . (canceled) 
     
     
         12 . A method for treating or preventing Parkinson's disease in a patient, the method comprising administering to the patient a therapeutically effective population of neuronal cells transformed with a nucleic acid molecule encoding sex determining protein (SRY), wherein the transformed cells express SRY. 
     
     
         13 . A method according to  claim 12  wherein the nucleic acid molecule encoding SRY is under the control of a heterologous promoter. 
     
     
         14 . A method according to  claim 12  wherein the population of neuronal cells comprises at least 95% stable, post-mitotic human NT2N cells. 
     
     
         15 . A method according to  claims 12  wherein the population of neuronal cells is injected into the brain of the patient. 
     
     
         16 . A method according to  claim 15  wherein the population of neuronal cells is injected at or near the region of the substantia nigra. 
     
     
         17 . A method according to  claim 16  wherein the population of neuronal cells is injected into the cordate or putamen of the substantia nigra. 
     
     
         18 . A method of treating Parkinson's disease, comprising the steps of:
 diagnosing a patient as having Parkinson's disease; and   injecting into the patient's brain a formulation comprising a pharmaceutically acceptable carrier and a therapeutically effective population of neuronal cells transformed with a nucleic acid molecule encoding sex determining protein (SRY), wherein the transformed cells express SRY;   wherein the nucleic acid molecule encoding SRY is under the control of a heterologous promoter.   
     
     
         19 . A method according to  claim 18 , wherein the population of neuronal cells comprises at least 95% stable, post-mitotic human NT2N cells. 
     
     
         20 . A method according to  claim 18 , wherein the population of neuronal cells comprises at least 96% stable, post-mitotic human NT2N cells. 
     
     
         21 . A method according to  claim 18 , wherein the population of neuronal cells comprises at least 97% stable, post-mitotic human NT2N cells. 
     
     
         22 . A method according to  claim 18 , wherein the population of neuronal cells comprises at least 98% stable, post-mitotic human NT2N cells. 
     
     
         23 . A method according to  claim 18 , wherein the population of neuronal cells comprises at least 99% stable, post-mitotic human NT2N cells. 
     
     
         24 . A method according to  claim 18 , wherein the population of neuronal cells comprises substantially pure, post-mitotic human NT2N cells.

Join the waitlist — get patent alerts

Track US2010260732A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.